RE:RE:RE:RE:RE:RE:List goes on and onPure speculation unfortuately. If true the company is missing a high opportunity by not saying as much in a PR.
However there are the management notes issued with the Q3 financials where the company can provide more comprehensive updates on the phase 2 trial, their development work on other cancer treatments and the vaccine initiative.
Hopefully they use the opportunity wisely.